Trusted Resource for Clinical Trials, Protocols & Progress
Ethics Committees—commonly referred to as Institutional Review Boards (IRBs) in the US or Independent Ethics Committees (IECs) elsewhere—are essential for safeguarding the rights, safety, and well-being of human participants in clinical research. With the globalization of trials, these committees play a critical role in ensuring ethical compliance across diverse regulatory environments.
Click to read the full article.
As clinical trials increasingly span multiple countries, navigating the ethical review landscape has become a complex undertaking. Although globally anchored in ICH-GCP and the Declaration of Helsinki, each country applies its own ethical standards, regulatory mandates, and documentation protocols for clinical trial oversight. These differences can lead to challenges in trial startup timelines, inconsistencies in protocol approval, and confusion regarding informed consent requirements.
Click to read the full article.
The ethical review process is the cornerstone of protecting human participants in clinical research. It ensures that trial protocols uphold scientific integrity while safeguarding the rights, safety, and dignity of participants. A robust ethical review not only complies with regulatory requirements (such as ICH-GCP and local laws) but also builds public trust and improves data credibility.
Click to read the full article.
As clinical research increasingly spans continents, pharmaceutical sponsors and contract research organizations (CROs) are encountering substantial ethical, regulatory, and operational hurdles. Multinational trials must secure ethical approval across multiple jurisdictions, each with its own legal frameworks, committee structures, and cultural values. While the goal is to protect participants and ensure scientific integrity, variability in review standards creates delays and inconsistencies.
Click to read the full article.
Public health emergencies such as pandemics, bioterrorism threats, or natural disasters require rapid responses. Clinical trials launched under these conditions are subject to unique ethical scrutiny. The urgency of treatment discovery and deployment must be balanced with the core ethical principles of autonomy, beneficence, non-maleficence, and justice. Emergency Use Protocols (EUPs) push Ethics Committees (ECs) and Institutional Review Boards (IRBs) to act swiftly—sometimes within days—to evaluate risk, consent strategies, and societal benefit.
Click to read the full article.
Ethical approval of a clinical trial is not a one-time event. Once a study begins, ethics committees (also known as Institutional Review Boards or IRBs) are obligated to provide continuous oversight to safeguard participants’ rights, safety, and well-being throughout the entire trial lifecycle. Regulatory bodies like ICH-GCP, FDA, EMA, and CDSCO mandate that ethical review continues in real-time as new information becomes available, such as safety concerns, protocol amendments, or deviations.
Click to read the full article.
In clinical trials, vulnerable populations are individuals or groups with diminished autonomy or capacity to give fully informed consent. These include children, pregnant women, prisoners, economically disadvantaged individuals, people with cognitive impairments, and the elderly. According to ICH-GCP (E6 R2), additional safeguards are required to protect their rights, safety, and well-being.
Click to read the full article.
One of the core responsibilities of Ethics Committees (ECs) is to ensure that the risks posed to participants in a clinical trial are justified by the potential scientific and social value of the research. This concept, embedded in ICH-GCP and national regulations worldwide, is central to ethical trial conduct. An ethically sound trial must demonstrate that it is scientifically necessary, methodologically valid, and poses no more than minimal or justifiable risk to participants.
Click to read the full article.
Standard Operating Procedures (SOPs) are foundational documents that govern the operations of Institutional Ethics Committees (IECs) or Institutional Review Boards (IRBs). SOPs not only ensure consistency, regulatory compliance, and quality assurance but also establish transparency in decision-making processes. Without clear SOPs, ECs are vulnerable to deviations, regulatory findings, and ethical lapses—especially in multicenter, multinational trials.
Click to read the full article.
Ethics Committees—referred to as Institutional Review Boards (IRBs) in the United States and Independent Ethics Committees (IECs) in the European Union—are cornerstones of human subject protection in clinical trials. Their role is mandated under the ICH-GCP E6 guideline and reinforced by national regulations worldwide. These committees are charged with ensuring that research involving human participants is scientifically valid, ethically justified, and compliant with both regulatory and moral standards. As globalization increases the number of multinational studies, understanding the diverse roles of ethics committees across regions becomes essential for sponsors, investigators, and regulators.
Click to read the full article.
